Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
We break down expense ratios across popular index funds and show how choosing the lowest-cost options can improve long-term retirement outcomes.
28,023 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Safe Labs launches a euro-denominated yield program using a Morpho vault and the MiCA-compliant EURCV stablecoin from...
Winter is signaling a shift in the housing market. Demand is creeping back as buyers expect holiday discounts, while ...
Claude AI projects a multi-year rally for XRP, SOL, and ADA, with end-2026 targets that would mark fresh highs amid i...
Oil trades near the mid-80s as geopolitics lift tanker demand. Frontline, Nordic American Tankers, and DHT Holdings l...
Nvidia has committed $2 billion to Nebius Group, accelerating Nebius’s role in the neocloud era. The move includes ea...
Meta Platforms is ending Horizon Worlds as a standalone VR social platform and redirecting capital to AI infrastructu...
Investors are eyeing AAR's AIR 2026 earnings call for clues on aftermarket demand, margins, and guidance. This articl...
Alphabet’s Q1 2026 results show a rapid profit pace that dwarfs Meta’s earnings, underscoring a widening gap in AI-dr...
Iran has replied to the latest U.S. ceasefire proposal via Pakistani mediators, demanding a permanent end to the war ...
The WHO has declared the latest ebola outbreak a public health emergency of international concern, prompting a wave o...
Bitcoin jumped toward $77,000 after early reports of a breakthrough in Iran peace talks sparked risk-on trading. Anal...